Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacc.2025.01.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hyperkalemia in Heart Failure with Reduced Ejection Fraction: Implications and Management.
Heart Fail Rev
August 2025
Duke Clinical Research Institute, Durham, NC, USA.
Hyperkalemia is a potentially life-threatening electrolyte imbalance that has traditionally posed significant challenges in the management of heart failure (HF). This review explores the complex interplay between hyperkalemia and the use of guideline-directed medical therapies (GDMT), such as renin-angiotensin-aldosterone system inhibitors (RAASi) and steroidal mineralocorticoid receptor antagonists (sMRAs), including spironolactone and eplerenone, which are currently recommended in guidelines for improving outcomes in heart failure with reduced ejection fraction (HFrEF). While these therapies reduce mortality and hospitalizations in HFrEF, their benefit in patients with heart failure with left ventricular ejection fraction (LVEF) ≥ 40% remains less conclusive.
View Article and Find Full Text PDFPolyethylene Glycol Surface Modification and Polythiophene Side-Chain Chemistry: A Combined Strategy toward High-Capacity Lithium-Ion Battery Anodes.
ACS Appl Energy Mater
August 2025
Department of Chemical and Bimolecular Engineering, Lehigh University, Bethlehem, Pennsylvania 18015, United States.
In the development of high-capacity lithium-ion batteries (LIBs), the combined optimization of active material interfaces and polymer binder chemistry plays a critical role in improving electrode performance and longevity. This work explores a dual design strategy incorporating polyethylene glycol (PEG) surface modification and carboxylated polythiophene side-chain tailoring to enhance the electrochemical behavior of magnetite (FeO)-based anodes. PEG is employed to improve interfacial stability, while carboxylated polythiophene binders with varying alkyl side-chain lengthspoly-[3-(potassium-4-butanoate)-thiophene-2,5-diyl] (P3KBT), poly-[3-(potassium-5-pentanoate)-thiophene-2,5-diyl] (P3KPT), and poly-[3-(potassium-6-hexanoate)-thiophene-2,5-diyl] (P3KHT)are used to modulate molecular interactions and ion transport.
View Article and Find Full Text PDFExploring the Influence of NaOH Catalyst on the Durability of Liquid Calcium Aluminate Cement Concrete.
Materials (Basel)
August 2025
Department of Mechanical Engineering, National Yunlin University of Science and Technology, Douliu City 64002, Taiwan.
Liquid calcium aluminate cement (LCAC) is an innovative material technology with significant potential for varied applications in civil engineering. However, despite its promising results, a significant gap remains in the direct application of LCAC as a concrete binder. The primary catalysts for LCAC are sodium hydroxide (NaOH) and potassium hydroxide (KOH).
View Article and Find Full Text PDFOptimizing care for chronic kidney disease: Considerations from A to Z.
J Chin Med Assoc
August 2025
Department of Medicine, Division of Nephrology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Chronic kidney disease (CKD) management requires a comprehensive and multidisciplinary approach to optimize clinical outcomes. This review systematically outlines essential components of CKD care from A to Z, offering evidence-based guidance to enhance patient management. Anemia treatment emphasizes iron supplementation, erythropoiesis-stimulating agents, and novel hypoxia-inducible factor prolyl hydroxylase inhibitors.
View Article and Find Full Text PDFManagement of patients with heart failure at high risk of hyperkalaemia: The CARE-HK in HF registry.
Eur J Heart Fail
August 2025
Saint Luke's Mid America Heart Institute and University of Missouri, Kansas City, MO, USA.
Aims: Patients with heart failure (HF) at high risk for hyperkalaemia are underrepresented in prospective HF registries. The CARE-HK in HF registry sought to characterize prospectively the clinical profile, management, and outcomes for patients with HF at high risk of hyperkalaemia.
Methods And Results: CARE-HK in HF was a multinational prospective registry of outpatients with HF (regardless of left ventricular ejection fraction [LVEF]) treated with an angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker/angiotensin receptor-neprilysin inhibitor (ACEI/ARB/ARNI) and either receiving or potential candidate for a mineralocorticoid receptor antagonist (MRA).